The U.S. Food and Drug Administration (FDA) has approved Armlupeg (pegfilgrastim-unne) 6 milligrams per 0.6 milliliter (mg/mL ...

India-based firm Lupin has joined the pegfilgrastim parade with the FDA’s approval of Armlupeg (pegfilgrastim-unne), the ...

Lupin receives USFDA approval for Armlupeg, a biosimilar to Neulasta, enhancing treatment options for cancer patients.

Neulasta Delivery Kit Provides Administration Option for Patients who may not Otherwise Need to Return to Clinic or Hospital the day After Chemotherapy One of the most common side effects of ...

The Food and Drug Administration approves Nyvepria, the biosimilar to Neulasta, to help treat and prevent infections in patients undergoing myelosuppressive chemotherapy. The Food and Drug ...

Stimufend ® (pegfilgrastim-fpgk), a biosimilar to Neulasta ® (pegfilgrastim), has been made available by Fresenius Kabi. Stimufend, a leukocyte growth factor, is indicated to decrease the incidence of ...

Armlupeg is indicated to reduce infection risk, specifically febrile neutropenia, in non-myeloid cancer patients.

Lupin has received USFDA approval for its biosimilar Armlupeg (pegfilgrastim-unne) injection, to be manufactured at its Pune ...

The OBI is intended to facilitate timed delivery of the correct dose of Neulasta and to improve the quality of life of patients as it removes the burden to return to a healthcare setting the day ...

The front page of the Feb. 26 Gazette featured an article on the extraordinary cost of cancer treatment. However, the article failed to discuss any potential solutions, such as the ability to lower ...

Neulasta Delivery Kit Provides Administration Option for Patients who may not Otherwise Need to Return to Clinic or Hospital the day After Chemotherapy THOUSAND OAKS, Calif., March 2, 2015 /PRNewswire ...

Lupin receives USFDA approval for Armlupeg, a biosimilar to Neulasta, used to treat neutropenia in cancer patients. Read more ...